CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-10
DOI
10.3389/fimmu.2022.927153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HMGB1-Mediated Restriction of EPO Signaling Contributes to Anemia of Inflammation
- (2022) Brian M Dulmovits et al. BLOOD
- Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies
- (2022) Do Hwan Kim et al. BLOOD
- FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
- (2022) Poornima Sharma et al. CLINICAL CANCER RESEARCH
- High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
- (2022) Yuanyan Tang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
- (2022) Derek P. Wong et al. Nature Communications
- Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
- (2022) Leah M. Alabanza et al. Frontiers in Immunology
- Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
- (2022) Marc Wehrli et al. Journal for ImmunoTherapy of Cancer
- Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia
- (2022) Paul Michael Maciocia et al. BLOOD
- Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
- (2022) Ricardo D. Parrondo et al. Blood Cancer Journal
- Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
- (2022) Quanjun Yang et al. OncoImmunology
- Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
- (2022) Saar I Gill et al. Blood Advances
- A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma
- (2021) Di Wang et al. BLOOD
- Preclinical and linical in himeric Antigen Receptor Therapy for ematological alignancies
- (2021) Zhenling Guo et al. CANCER SCIENCE
- Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia
- (2021) Guoqiang Lin et al. Molecular Medicine Reports
- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
- (2021) Max Jan et al. Science Translational Medicine
- DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities
- (2021) Tian Deng et al. Cell Death & Disease
- Cytokines in CAR T Cell–Associated Neurotoxicity
- (2021) Juliane Gust et al. Frontiers in Immunology
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
- (2021) John H. Baird et al. Blood Advances
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML
- (2021) Martin Wermke et al. BLOOD
- CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial
- (2021) Mi Shao et al. BONE MARROW TRANSPLANTATION
- A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
- (2021) Yang Wu et al. CANCER GENE THERAPY
- Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
- (2021) Jessica Wenthe et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
- (2021) Mehmet Kemal Samur et al. Nature Communications
- Direct control of CAR T cells through small molecule-regulated antibodies
- (2021) Spencer Park et al. Nature Communications
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
- (2021) Deming Duan et al. Frontiers in Immunology
- A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
- (2021) Chunrui Li et al. Clinical and Translational Medicine
- CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity
- (2021) Tim Sauer et al. BLOOD
- Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
- (2021) Guoxing Zhao et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
- (2021) Meijing Liu et al. CANCER SCIENCE
- Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
- (2021) Lisa C. Holthof et al. CLINICAL CANCER RESEARCH
- CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
- (2021) Sabrina Prommersberger et al. GENE THERAPY
- Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
- (2021) Francesco Paolo Tambaro et al. LEUKEMIA
- Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
- (2021) Dina Schneider et al. Science Translational Medicine
- A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL
- (2021) Yue Tan et al. Blood Cancer Journal
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
- (2021) Kai Rejeski et al. BLOOD
- Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML)
- (2021) Hardikkumar Jetani et al. BLOOD
- CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
- (2021) Timothy N. J. Bullock Cellular & Molecular Immunology
- Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia
- (2021) Lichun Xie et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
- (2021) Jing Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
- (2021) Qingya Cui et al. Journal of Hematology & Oncology
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL
- (2021) Samanta Romina Zanetti et al. MOLECULAR THERAPY
- Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies
- (2021) Sanmei Wang et al. ONCOLOGY REPORTS
- Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
- (2021) Haibo Zhu et al. OncoTargets and Therapy
- CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
- (2021) Guoqing Wei et al. Cancer Immunology Research
- Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
- (2021) Ping Li et al. Frontiers in Immunology
- Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
- (2021) Haobin Deng et al. Frontiers in Immunology
- CAR T-cell therapy for multiple myeloma: state of the art and prospects
- (2021) Niels W C J van de Donk et al. Lancet Haematology
- Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
- (2021) Rebecca Baur et al. Journal for ImmunoTherapy of Cancer
- IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
- (2021) Anthony M. Battram et al. Cancers
- Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy
- (2021) Andrew J. Johnsrud et al. Blood Advances
- The blood–brain barrier in systemic infection and inflammation
- (2021) Ian Galea Cellular & Molecular Immunology
- Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
- (2021) Matias Autio et al. CLINICAL CANCER RESEARCH
- Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy
- (2021) Arianna Pocaterra et al. CURRENT OPINION IN IMMUNOLOGY
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
- (2021) Heng Mei et al. Journal of Hematology & Oncology
- CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
- (2021) Jiangzhou Shi et al. Journal of Hematology & Oncology
- Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy
- (2021) Rujiao Dong et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
- (2021) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
- (2021) Nathan Hale Fowler et al. NATURE MEDICINE
- An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma
- (2021) Paul-Joseph Aspuria et al. Science Translational Medicine
- A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
- (2021) Qian Zhang et al. Science Translational Medicine
- Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
- (2021) Nadia El Khawanky et al. Nature Communications
- Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
- (2021) Di Wang et al. Blood Cancer Journal
- Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
- (2021) Yimei Que et al. Frontiers in Immunology
- 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
- (2021) Emiliano Roselli et al. Journal for ImmunoTherapy of Cancer
- Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
- (2021) Limin Xing et al. Frontiers in Oncology
- The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
- (2021) Débora Bifano Pimenta et al. Frontiers in Cell and Developmental Biology
- Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
- (2021) Krishna R. Juluri et al. Blood Advances
- Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
- (2021) Timothy J. Voorhees et al. Blood Advances
- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
- (2020) Jordan Gauthier et al. BLOOD
- Selinexor‐based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
- (2020) Ajai Chari et al. BRITISH JOURNAL OF HAEMATOLOGY
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
- (2020) Sabarinath V. Radhakrishnan et al. Nature Communications
- Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
- (2020) D. Wang et al. Blood Cancer Journal
- Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
- (2020) Shuangyou Liu et al. Blood Cancer Journal
- A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
- (2020) Rebecca Epperly et al. Frontiers in Oncology
- Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
- (2020) Yuying Liu et al. Science Immunology
- Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation.
- (2020) Maria-Luisa Schuber et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
- (2020) Jessica Wenthe et al. CANCER GENE THERAPY
- Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
- (2020) Wenting Song et al. CLINICAL IMMUNOLOGY
- CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells
- (2020) Marika Guercio et al. HAEMATOLOGICA
- Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma
- (2020) Christopher M. Wright et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
- (2020) Shiwani Agarwal et al. MOLECULAR THERAPY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia
- (2020) Simon Loff et al. Molecular Therapy-Oncolytics
- Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
- (2020) Lisa C. Holthof et al. Cancers
- Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
- (2020) Chuan Tong et al. BLOOD
- How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies
- (2020) Joshua A. Hill et al. BLOOD
- Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
- (2020) Binod Dhakal et al. BONE MARROW TRANSPLANTATION
- Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
- (2020) Paolo Strati et al. HAEMATOLOGICA
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
- (2020) Cesar Sommer et al. MOLECULAR THERAPY
- Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
- (2020) Carsten Riether et al. NATURE MEDICINE
- Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
- (2020) Wei Sang et al. Cancer Medicine
- Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
- (2020) Meir Rozenbaum et al. Frontiers in Immunology
- 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
- (2020) Matteo Libero Baroni et al. Journal for ImmunoTherapy of Cancer
- SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
- (2020) Jia Wei et al. Journal for ImmunoTherapy of Cancer
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
- (2020) Tania Jain et al. Blood Advances
- Macrophage, the potential key mediator in CAR-T related CRS
- (2020) Zhaonian Hao et al. Experimental Hematology & Oncology
- Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
- (2020) Eugenio D. Hottz et al. BLOOD
- Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
- (2020) Meijing Liu et al. CANCER SCIENCE
- Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells
- (2020) Martin Štach et al. CYTOTHERAPY
- Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies
- (2020) Takayuki Ikezoe INTERNATIONAL JOURNAL OF HEMATOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
- (2020) Qing Deng et al. NATURE MEDICINE
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
- (2020) TingTing Tang et al. PHARMACOLOGY & THERAPEUTICS
- Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
- (2020) Liangshun You et al. Frontiers in Immunology
- Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
- (2020) Lu Han et al. Journal for ImmunoTherapy of Cancer
- CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia
- (2020) Guozhu Xie et al. Nature Biomedical Engineering
- Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management
- (2020) Shiqi Li et al. CLINICAL CANCER RESEARCH
- IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity
- (2019) Darya Alizadeh et al. Cancer Immunology Research
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators
- (2019) Mohit Sachdeva et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
- (2019) Moo-Kon Song et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
- (2019) Sattva S. Neelapu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
- (2019) Huiwen Jiang et al. ANNALS OF HEMATOLOGY
- Chimeric antigen receptor T cell persistence and memory cell formation
- (2019) Alexander D McLellan et al. IMMUNOLOGY AND CELL BIOLOGY
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect and changes in PD‑1 expression of CD19 CAR‑T�cells from T�cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor
- (2019) Rui Zhang et al. ONCOLOGY REPORTS
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
- (2019) Eric L. Smith et al. Cancer Immunology Research
- Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
- (2019) Austin J. Sim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
- (2019) Sujun Li et al. OncoTargets and Therapy
- Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
- (2019) Jianxia Zhou et al. Protein & Cell
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Selinexor: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide
- (2019) Melissa Works et al. MOLECULAR CANCER THERAPEUTICS
- Anemia of Inflammation
- (2019) Tomas Ganz NEW ENGLAND JOURNAL OF MEDICINE
- CAR‑T 19 combined with reduced‑dose PD‑1 blockade therapy for treatment of refractory follicular lymphoma: A case report
- (2019) Jia Wang et al. Oncology Letters
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
- (2019) Yaqing Cao et al. Frontiers in Oncology
- Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
- (2019) Ying Wang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
- (2019) Hui Luo et al. Journal for ImmunoTherapy of Cancer
- The immune landscape and response to immune checkpoint blockade therapy in lymphoma
- (2019) Justin Kline et al. BLOOD
- CD4 Helper and CD8 Cytotoxic T Cell Differentiation
- (2018) Ichiro Taniuchi Annual Review of Immunology
- Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
- (2018) Michelle A. Fanale et al. BLOOD
- The potential role of γδ T cells after allogeneic HCT for leukemia
- (2018) Rupert Handgretinger et al. BLOOD
- Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
- (2018) Jae H Park et al. CLINICAL INFECTIOUS DISEASES
- CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
- (2018) Jinghua Wang et al. Journal of Hematology & Oncology
- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner
- (2018) Romy Loschinski et al. Oncotarget
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- (2018) Mauro P. Avanzi et al. Cell Reports
- Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias
- (2018) Vito Pistoia et al. Frontiers in Immunology
- In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
- (2018) Anett Pfeiffer et al. EMBO Molecular Medicine
- A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
- (2018) Samuel John et al. MOLECULAR THERAPY
- Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape
- (2018) Carl DeSelm et al. MOLECULAR THERAPY
- In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas
- (2018) Carlos A. Ramos et al. MOLECULAR THERAPY
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Yongxian Hu et al. BONE MARROW TRANSPLANTATION
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
- (2018) Marion Alcantara et al. LEUKEMIA
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche
- (2017) Fotis Asimakopoulos et al. JOURNAL OF LEUKOCYTE BIOLOGY
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
- (2017) J Pan et al. LEUKEMIA
- Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
- (2017) Iulia Diaconu et al. MOLECULAR THERAPY
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
- (2017) Paul M Maciocia et al. NATURE MEDICINE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
- (2017) Michael D. Jain et al. STEM CELLS
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
- (2017) Marco Ruella et al. Cancer Discovery
- CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
- (2017) Crystal L. Mackall et al. Cancer Discovery
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia
- (2016) Saad S. Kenderian et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
- (2016) Vishwajith Sridharan et al. BRITISH JOURNAL OF CANCER
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
- (2016) Paulina J. Paszkiewicz et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
- (2016) Yongxian Hu et al. Journal of Hematology & Oncology
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- +/CD19+ lymphocytes
- (2015) I. Airoldi et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
- (2015) K Pinz et al. LEUKEMIA
- Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
- (2015) Aoi Shiomi et al. MEDIATORS OF INFLAMMATION
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Individual Motile CD4 + T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
- (2015) Ivan Liadi et al. Cancer Immunology Research
- Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function
- (2014) Chunjian Qi et al. CANCER INVESTIGATION
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival
- (2014) Y. Kikushige et al. JOURNAL OF IMMUNOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
- (2014) Samuel T Workenhe et al. OncoImmunology
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- (2013) Liza B John et al. OncoImmunology
- Tumor cell recognition by γδ T lymphocytes
- (2013) Daniel V. Correia et al. OncoImmunology
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
- (2012) N. Cieri et al. BLOOD
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- An Interleukin-21- Interleukin-10-STAT3 Pathway Is Critical for Functional Maturation of Memory CD8+ T Cells
- (2011) Weiguo Cui et al. IMMUNITY
- The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis
- (2011) I. Mavroudi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to T-cell cytotoxicity
- (2010) T. Lanca et al. BLOOD
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-α and IL-1β
- (2009) Mohammad M. Khan et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Blockade of IL-15 activity inhibits microglial activation through the NFκB, p38, and ERK1/2 pathways, reducing cytokine and chemokine release
- (2009) Diego Gomez-Nicola et al. GLIA
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells
- (2008) W. J. CAO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now